Barclays lowered the firm’s price target on Tango Therapeutics to $13 from $18 and keeps an Overweight rating on the shares. The firm noted that Tango discontinued its USP1 inhibitor, TNG348, due to liver toxicity, and the firm is thus removing it from its model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX: